Clinical trials: Post-exposure Prophylaxis
Influenza, Human, Respiratory Tract Infections
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in…
- Conditions
- Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
- Trial name
- Pearlstone (NCT07827599)
- Testing
- Baloxavir marboxil
- Where
- 8 sites in China
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Rabies Post-exposure Prophylaxis, Rabies
Real-World Effectiveness of Zamerovimab and Mazorelvimab and Vaccine for Rabies Grade III Exposure in Nanyang
The objective of this real-world, prospective observational study is to evaluate the clinical effectiveness of zamerovimab and mazorelvimab injection (a human rabies monoclonal antibody cocktail) administered in combination with…
- Trial name
- NCT07624461
- Testing
- Zamerovimab and Mazorelvimab Injection plus Rabies Vaccine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Rabies Post-exposure Prophylaxis
Real World Evidence Study of SYN023 in Children Exposed to Rabies
This observational study is an open-label, prospective, multi-center design. The goal is to evaluate the long-term clinical survival outcomes at 3 months and 1 year in individuals under 18 years of age with WHO Category III…
- Trial name
- NCT07327307
- Where
- 6 sites in China
- Volunteers
- 232 people
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Rabies Post-exposure Prophylaxis
SYN023 With Rabies Vaccine in Healthy Pediatric Subjects
This study is a randomized, double-blind, active-controlled design. The goal is to evaluate the safety, pharmacokinetics and pharmacodynamic of SYN023 in combination with rabies vaccine in healthy participants under 18 years of…
- Trial name
- NCT07342257
- Testing
- SYN023, Rabies Vaccine, HRIG
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Post Exposure Prophylaxis
Impact of Health Education on Knowledge, Attitude and Practice of Post-exposure Prophylaxis
Occupational exposure to blood-borne pathogens, such as human immune-deficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) for healthcare workers through contact with human blood and body fluids has become…
- Trial name
- NCT07330427
- Testing
- Health Education
- Where
- Egypt
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Aswan University
Rabies Post-exposure Prophylaxis
Study to Evaluate GR1801's Efficacy and Safety
The goal of this clinical trial is to compare the efficacy and safety of GR1801 injection with Human Rabies Immunoglobulin(HRIG) in patients with WHO Category 3 rabies exposure. Patients will receive GR1801 injection or HRIG.
- Trial name
- NCT05846568
- Testing
- GR1801, Human Rabies Immunoglobulin(HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Post-exposure Prophylaxis, Sexually Transmitted Diseases
Pharmacokinetic Characterization of a Single 200 mg Dose of Doxycycline in Post-exposure Prophylaxis (PEP) of Sexually Transmitted Infections in Different Biological Compartments
Post-exposure prophylaxis (PEP) using doxycycline 200 mg within 24 hours of unprotected sexual intercourse to prevent sexually transmitted infections has demonstrated a reduction in the incidence of chlamydial and syphilis…
- Conditions
- Post-exposure Prophylaxis, Sexually Transmitted Diseases, Doxycycline
- Trial name
- DOXY-PK (NCT06007534)
- Testing
- Samples
- Where
- 2 sites in France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rabies Post-exposure Prophylaxis
Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia
A rabies virus neutralizing antibody (RVNA) concentration ≥ 0.5 IU/ml at 14 days after immunization is considered a proxy for protection in vaccine efficacy studies.
- Trial name
- NCT05684185
- Testing
- Intramuscular (IM) rabies post-exposure prophylaxis, Intradermal (ID) rabies post-exposure prophylaxis
- Where
- Cambodia
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Knowledge, Attitudes, Practice, Post-exposure Prophylaxis
Comic Intervention for Sexual Violence Prevention and Post-rape Care
In humanitarian settings, sexual and gender-based violence disproportionately impacts women and children. However, there continues to be a lack of evidence regarding both sexual violence prevention and post-rape care…
- Trial name
- NCT04656522
- Testing
- Participatory Comic Intervention
- Where
- 2 sites in Canada, Uganda
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Coronavirus Infections, Post-exposure Prophylaxis
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
COVID-19 has rapidly evolved into a generalized global pandemic. Post-exposure prophylaxis (PEP) against on COVID-19 was identified as an urgent research priority by the WHO, and lopinavir/ritonavir (LPV/r) is a promising…
- Trial name
- CORIPREV-LR (NCT04321174)
- Testing
- Lopinavir/ritonavir
- Where
- 4 sites in Canada
- Volunteers
- 123 people
- Sponsor
- Unity Health Toronto
Coronavirus Disease 2019 (COVID-19), Post-Exposure Prophylaxis
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers
Background: The rapid spread and high infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) makes identifying an effective prophylaxis agent highly important.
- Trial name
- NCT04438837
- Testing
- Hydroxychloroquine
- Where
- Israel
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men
Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.
This study aims to describe the safety, tolerability and adherence to the coformulated anti-HIV drug tenofovir-emtricitabine-rilpivirine (eviplera) when given to men who have sex with men (MSM) following an actual or potential…
- Trial name
- EPEP (NCT01715636)
- Testing
- Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg
- Where
- 4 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Andrew Carr
Rabies Post-exposure Prophylaxis
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
- Trial name
- NCT00345319
- Testing
- rabies vaccine
- Where
- China
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines